Scientific Studies

Unlike many other food supplements, Bimuno® is underpinned by a large and growing body of published scientific evidence.


B-GOS (commercially available as Bimuno®) is the result of intensive research & development dating back from 2000 and conducted in collaboration with the University of Reading’s Food Microbial Sciences Unit and other globally recognized research institutes.

The result of this research was the development of Bimuno, a multi-functional supplement based around a unique and patent-protected, galactooligosaccharide formulation. It is the most advanced and only 2nd generation prebiotic and as such offers additional functionality over and above its prebiotic and bifidogenic effect.

Recent clinical trials prove that Bimuno’s unique properties go well beyond its advanced prebiotic action.

Bimuno® acts via a triple mode of action in the gut. It has been proven to

  1. Positively rebalance gut microflora by selectively promoting health-promoting bacteria (bifidobacteria)
  2. Prevent adhesion of bacterial pathogens, thereby helping protect against infections
  3. Help combat chronic inflammation (via its direct action with the immune system) that causes many debilitating, long term illnesses

A number of clinical trials have been completed and subsequent trials will continue to be the focus of ongoing research in this very exciting area which is aimed at helping maintain the gut health and general wellbeing of your customers and patients.

The research is on-going and is mainly focusing in the exciting area of chronic inflammation aimed at combating the many debilitating long term illnesses.


Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers

The present study explored the effects of two prebiotics on the secretion of the stress hormone, cortisol and emotional processing in healthy volunteers.

Read More

Influence of Galacto-Oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons

It is recognised that ageing induces various changes to the human colonic microbiota. Most relevant is a reduction in bifidobacteria, which is a health-positive genus.

Read More

A mixture of trans-Galacto-Oligosaccharides reduces markers of Metabolic Syndrome and modulates the fecal microbiota and immune function of overweight adults

Investigation into the efficacy of trans-galactooligosaccharide (B-GOS) in altering the colonic microflora of overweight individuals and its impact on risk factors of metabolic syndrome.

Read More

A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel Galacto-Oligosaccharide mixture (B-GOS) in reducing travellers’ diarrhoea.

This study assessed the effectiveness of a prebiotic galacto-oligosaccharide mixture (B-GOS) on the severity and/or incidence of travellers’ diarrhoea (TD) in healthy subjects.

Read More

The effects of a Trans-Galacto-Oligosaccharide (B-GOS) prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.

Investigation into the efficacy of a novel prebiotic trans-galactooligosaccharide (B-GOS) in changing colonic microflora and improve the symptoms in IBS sufferers.

Read More

Modulation of the faecal microflora profile and immune function by a novel Trans-Galacto-Oligosaccharide mixture (B-GOS) in healthy elderly volunteers.

We assessed the effect of a prebiotic GOS mixture (B-GOS) on immune function and faecal microflora composition in healthy elderly subjects.

Read More

Prebiotic evaluation of a novel Galacto-Oligosaccharide mixture (B-GOS) produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans

Assesment of the prebiotic potential of a novel galactooligosaccharide produced through the action of β-galactosidases, originating from a probioticBifidobacterium bifidumstrain, against a galactooligosaccharide produced through the action of an industrial β-galactosidase and a placebo.

Read More

A mixture containing Galacto-Oligosaccharide (B-GOS), produced by the enzymatic activity of Bifidobacterium bifidum, reduces Salmonella enterica serovar Typhimurium infection in mice.

Hypothese that Bimuno® may confer some protection in the murine host from Salmonella enterica serovar Typhimurium (S. Typhimurium) infection.

Read More

A novel Galacto-Oligosaccharide mixture (B-GOS) increases the fermentation system and in the proximal colonic contents of pigs in-vivo.

The prebiotic potential of a novel galactooligosaccharide GOS (B-GOS) mixture, produced by the activity of galactosyltransferases from Bifidobacterium bifidum 41171 on lactose, was assessed in-vitro and in a parallel continuous randomised pig trial.

Read More

Development and functional properties of Bimuno®: a second-generation prebiotic mixture.

Prebiotic carbohydrates are recognised for their ability to selectively increase the levels of health-promoting bacteria, mainly bifidobacteria and lactobacilli, in the intestine of humans and animals

Read More



Back to Healthcare Professional Section


This section is an information and educational resource for healthcare professionals, scientists, researchers and journalists. It is not intended for consumers. If you wish to purchase Bimuno please click here

Back to the top